Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Cash & Equivalents (2016 - 2025)

Macrogenics (MGNX) has disclosed Cash & Equivalents for 14 consecutive years, with $57.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 68.71% to $57.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.2 million through Dec 2025, down 68.71% year-over-year, with the annual reading at $57.2 million for FY2025, 68.71% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $57.2 million at Macrogenics, down from $80.1 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $224.3 million in Q1 2023, with the low at $21.5 million in Q2 2022.
  • Average Cash & Equivalents over 5 years is $122.4 million, with a median of $108.8 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents crashed 88.64% in 2022, then soared 406.58% in 2023.
  • Over 5 years, Cash & Equivalents stood at $123.5 million in 2021, then decreased by 11.81% to $108.9 million in 2022, then fell by 7.28% to $101.0 million in 2023, then soared by 81.11% to $182.8 million in 2024, then crashed by 68.71% to $57.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $57.2 million, $80.1 million, and $130.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.